Muutke küpsiste eelistusi

E-raamat: Nanomedicine and Neuroprotection in Brain Diseases

Edited by (Secretary of Research, Uppsala University Hospital, Uppsala University, Sweden), Edited by (Professor, Uppsala University, Sweden)
  • Formaat: 442 pages
  • Sari: Progress in Brain Research
  • Ilmumisaeg: 22-Sep-2021
  • Kirjastus: Elsevier - Health Sciences Division
  • Keel: eng
  • ISBN-13: 9780323901635
  • Formaat - EPUB+DRM
  • Hind: 272,93 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Lisa ostukorvi
  • Lisa soovinimekirja
  • See e-raamat on mõeldud ainult isiklikuks kasutamiseks. E-raamatuid ei saa tagastada.
  • Formaat: 442 pages
  • Sari: Progress in Brain Research
  • Ilmumisaeg: 22-Sep-2021
  • Kirjastus: Elsevier - Health Sciences Division
  • Keel: eng
  • ISBN-13: 9780323901635

DRM piirangud

  • Kopeerimine (copy/paste):

    ei ole lubatud

  • Printimine:

    ei ole lubatud

  • Kasutamine:

    Digitaalõiguste kaitse (DRM)
    Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale  Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).

    Vajalik tarkvara
    Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)

    PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )

    Seda e-raamatut ei saa lugeda Amazon Kindle's. 

Progress in Brain Research series, highlights new advances in the field, with this new volume presenting interesting chapters. Each chapter is written by an international board of authors.
  • Provides the authority and expertise of leading contributors from an international board of authors
  • Presents the latest release in the Progress in Brain Research series
  • Updated release includes the latest information on the Neuropharmacology of Neuroprotection
Contributors v
Acknowledgments xix
Preface xxi
Chapter 1 Alzheimer's disease neuropathology is exacerbated following traumatic brain injury. Neuroprotection by co-administration of nanowired mesenchymal stem cells and cerebrolysin with monoclonal antibodies to amyloid beta peptide
1(98)
Hari Shanker Sharma
Dafin F. Muresanu
Rudy J. Castellani
Ala Nozari
Jose Vicente Lafuente
Anca D. Buzoianu
Seaab Sahib
Z. Ryan Tian
Igor Bryukhovetskiy
Igor Manzhulo
Preeti K. Menon
Ranjana Patnaik
Lars Wiklund
Aruna Sharma
1 Introduction
2(9)
1.1 Blood-brain barrier leakage in AD patients
4(2)
1.2 Blood-borne factors influence AD brain pathology
6(2)
1.3 Specificity of amyloid beta peptide deposition in AD brain
8(2)
1.4 Mesenchymal stem cells and AD brain pathology
10(1)
2 Neurotrophic factors in AD
11(3)
2.1 Neurotrophic factors changes in human brain with AD
12(1)
2.2 Serotonin and oxidative stress in AD
13(1)
2.3 Antibodies to A0P is neuroprotective in AD
13(1)
3 Our observation of nanowired delivery of agents in AD
14(7)
3.1 Methodological consideration
14(1)
3.2 Alzheimer's disease model
15(1)
3.3 Concussive head injury
16(1)
3.4 Treatment strategies in AD
16(2)
3.5 Parameters measured
18(3)
3.6 Biochemical measurement
21(1)
4 Results
21(24)
4.1 Rat model of AD induced by ABP infusion
21(3)
4.2 Blood-brain bajrier breakdown in AD
24(4)
4.3 Brain edema formation in ABP infusion induced AD
28(3)
4.4 Brain pathology in A0P infusion induced AD
31(10)
4.5 Ultrastructural brain pathology in AD induced by ApP infusion
41(2)
4.6 Biochemical changes in ApP infusion induced AD model
43(1)
4.7 Concussive head injury exacerbated biochemical changes in CSF of ApP infusion induced AD
44(1)
5 Neuroprotective strategies in AD induced by ApP infusion
45(11)
5.1 Nanowired cerebrolysin with MSCs and ApPmAb reduces blood-brain barrier breakdown
46(1)
5.2 Nanowired cerebrolysin with MSCs and ApPmAb reduces brain edema formation
47(2)
5.3 Nanowired cerebrolysin with MSCs and ApPmAb reduces brain pathology
49(6)
5.4 Nanowired cerebrolysin with MSCs and ApPmAb reduces biochemical changes in CSF
55(1)
6 Discussion
56(4)
7 Conclusion and future perspectives
60(39)
Acknowledgments
61(1)
Conflict of interest
61(1)
References
62(37)
Chapter 2 Glioblastoma: What can we do for these patients today and what will we be able to do in the future?
99(20)
Igor Bryukhovetskiy
Aleksandra Kosianova
Sergeis Zaitsev
Oleg Pak
Aruna Sharma
Hari Shanker Sharma
1 Introduction
100(1)
2 Modem approach to GBM treatment
100(3)
3 Cancer stem cells
103(1)
4 Interaction of stem cells and cancer cells
104(3)
5 Immunotherapy and TGFp
107(1)
6 TGFp and targeted therapy
108(1)
7 Wnt-inhibitors in GBM treatment
109(1)
8 Nanotechnologies, cerebral edema and blood-brain barrier
110(3)
9 Conclusion
113(6)
References
114(5)
Chapter 3 Network pharmacological mechanism of Cinobufotalin against glioma
119(20)
Cong Li
Hanyu Guo
Chao Wang
Wengang Zhan
Qijia Tan
Caijun Xie
Aruna Sharma
Hari Shanker Sharma
Lin Chen
Zhiqiang Zhang
1 Introduction
120(1)
2 Materials and methods
121(1)
2.1 Compounds of Cinobufotalin and screening of related targets of Cinobufotalin
121(1)
2.2 Target network map of Cinobufotalin
121(1)
2.3 GO biological process and KEGG metabolic pathway of Cinobufotalin
122(1)
2.4 Prediction target genes of glioma
122(1)
3 Results
122(10)
3.1 Main active components and prediction targets of Cinobufotalin
122(1)
3.2 Analysis results of GO biological process and KEGG metabolic pathway
122(4)
3.3 Protein-protein interaction (PPI) network construction of Cinobufotalin
126(1)
3.4 Prediction of targets between Cinobufotalin and glioma
126(3)
3.5 KEGG pathway enrichment analysis between Cinobufotalin and glioma
129(3)
4 Discussion
132(7)
Funding
135(1)
References
135(4)
Chapter 4 Nanodelivery of oxiracetam enhances memory, functional recovery and induces neuroprotection following concussive head injury
139(92)
Feng Niu
Aruna Sharma
Zhenguo Wang
Lianyuan Feng
Dafin F. Muresanu
Seaab Sahib
Z. Ryan Tian
Jose Vicente Lafuente
Anca O. Buzoianu
Rudy J. Castellani
Ala Nozari
Preeti K. Menon
Ranjana Patnaik
Lars Wiklund
Hari Shanker Sharma
1 Introduction
140(3)
1.1 Dementia and neurodegeneration
142(1)
2 Alzheimer's disease
143(1)
3 Molecular mechanisms associated with neurodegenerative diseases
144(2)
3.1 Amyloid precursor protein
144(1)
3.2 α-Secretase
145(1)
3.3 Tau protein
145(1)
4 Traumatic brain injury induces Alzheimer's disease
146(1)
5 Inflammation and oxidative stress following neurodegenerative diseases
147(2)
6 Oxiracetam and brain function
149(2)
7 Nanodelivery of drug for neurological dysfunctions
151(3)
7.1 Materials and methods
152(2)
8 Nanoformulation of oxiracetam
154(8)
8.1 Materials
154(1)
8.2 Methods
155(1)
8.3 Characterization
155(7)
9 Results
162(35)
9.1 Nanowired oxiracetam characterization
162(1)
9.2 Oxiracetam and physiological variables in concussive head injury
162(4)
9.3 Oxiracetam and the blood-brain barrier in CHI
166(2)
9.4 Oxiracetam and cerebral blood flow in CHI
168(1)
9.5 Oxiracetam and brain edema formation in CHI
169(2)
9.6 Oxiracetam influences regional brain functions
171(8)
9.7 Oxiracetam influence biobehavioral changes in CHI
179(3)
9.8 Oxiracetam influences biochemical changes in CSF following CHI
182(2)
9.9 Oxiracetam and brain pathology
184(13)
10 Discussion
197(5)
11 Conclusion
202(1)
12 Future perspectives
202(29)
Acknowledgments
202(1)
Conflict of interest
203(1)
References
203(28)
Chapter 5 Clinical neurorestorative cell therapies for stroke
231(18)
Hongyun Huang
Gengsheng Mao
Lin Chen
Hari Shanker Sharma
1 Introduction
231(1)
2 Basic information of cell therapies
232(1)
3 Results of exploring trials or studies
233(3)
3.1 Neuron cells
233(1)
3.2 Mononuclear cells (MNCs)
234(1)
3.3 Mesenchymal stromal cells (MSCs)
235(1)
3.4 Olfactory ensheathing cells (OECs)
235(1)
3.5 Hemopoietic stem cells (HSTs)
236(1)
3.6 Mesenchymal stem cell products
236(1)
3.7 Neural stem cell products
236(1)
3.8 Combination cell therapy
236(1)
4 Results of multicenter, double-blind or observing-blind, randomized, placebo-controlled trials
236(3)
5 Discussion
239(1)
6 Summary
240(9)
Disclosure
240(1)
References
241(8)
Chapter 6 Nanodelivery of traditional Chinese Gingko Biloba extract EGb-761 and bilobalide BN-52021 induces superior neuroprotective effects on pathophysiology of heat stroke
249(68)
Seaab Sahib
Aruna Sharma
Dafin F. Muresanu
Zhiqiang Zhang
Cong Li
Z. Ryan Tian
Anca D. Buzoianu
Jose Vicente Lafuente
Rudy J. Castellani
Ala Nozari
Ranjana Patnaik
Preeti K. Menon
Lars Wiklund
Hari Shanker Sharma
1 Introduction
250(4)
1.1 Heat stress and heat wave induced mortality
252(1)
1.2 Heat shock proteins (HSPs) synthesis in heat stress
253(1)
2 Neurological dysfunction in hyperthermia
254(2)
2.1 Hyperthermia and cell signaling
255(1)
3 Cytokines release in hyperthermia
256(6)
3.1 Amino acid Neurotransmitters in hyperthermia
256(1)
3.2 Blood-brain barrier damage in hyperthermia
256(1)
3.3 Cerebral blood flow and metabolism disruption in hyperthermia
257(1)
3.4 Oxidative stress and brain pathology in hyperthermia
258(1)
3.5 Chinese traditional medicine extract of Gingko Biloba (EGb-761)
259(1)
3.6 Nanowires drug delivery to CNS
260(2)
4 Our observations on EGb-761 and BN-52021 on heat stress induced brain pathology
262(1)
5 Nanowired preparation of Gingko biloba extract
262(2)
5.1 Materials
262(1)
5.2 Fabrication of titanate nanowires
263(1)
5.3 Characterization
263(1)
5.4 Drug loading and delivery
264(1)
6 Heat Stress Model of hyperthermic brain injury
264(1)
6.1 Animals
264(1)
6.2 Exposure to heat stress
264(1)
7 Heat Stress symptoms
264(2)
8 Physiological parameters
266(1)
9 Pathophysiological parameters
267(4)
10 Statistical analyses
271(1)
11 Our findings in heat stress
271(1)
11.1 Stress symptoms
271(1)
12 Nociception
272(1)
13 Physiological variables
272(2)
14 Blood-brain barrier permeability
274(1)
15 Cerebral blood flow
274(3)
16 Brain edema formation and volume swelling
277(3)
17 Brain pathology after heat exposure
280(1)
18 EGb-761 treatment on heat exposure induced pathophysiology
280(4)
19 BN-52021 treatment on heat exposure induced pathophysiology
284(1)
20 NWEGb-761 treatment on chronic heat stressed induced pathophysiology
285(2)
21 NWBN-52021 treatment on chronic heat stressed induced pathophysiology
287(1)
22 Discussion
288(2)
23 Conclusion and future perspectives
290(27)
Acknowledgments
291(1)
Conflict of interest
291(1)
References
291(26)
Chapter 7 Upregulation of hemeoxygenase enzymes H0-1 and HO-2 following ischemia-reperfusion injury in connection with experimental cardiac arrest and cardiopulmonary resuscitation: Neuroprotective effects of methylene blue
317(60)
Lars Wiklund
Aruna Sharma
Ranjana Patnaik
Dafin F. Muresanu
Seaab Sahib
Z. Ryan Tian
Rudy J. Castellani
Ala Nozari
Jose Vicente Lafuente
Hari Shanker Sharma
1 Introduction
318(1)
2 Cerebral ischemia and reperfusion
319(2)
3 Mechanisms of neuronal cell death following ischemia/reperfusion
321(3)
3.1 Caspase dependent cell death
321(1)
3.2 Caspase independent cell death
322(1)
3.3 Free radical production following cerebral ischemia
322(2)
4 Hemeoxygenase enzymes HO-1 and HO-2 following ischemia-reperfusion injury
324(5)
4.1 Neuronal dysfunction following cardiac arrest and cardiopulmonary resuscitation
325(2)
4.2 Neuroprotective effects of methylene blue
327(2)
5 Our investigations on cardiac arrest and reperfusion induced brain pathology
329(2)
5.1 Methodological consideration
329(2)
6 Brain pathology in cardiac arrest
331(3)
6.1 Light microscopy
331(1)
6.2 Immunohistochemistry
332(1)
6.3 Albumin immunohistochemistry
332(1)
6.4 Glial fibrillary acidic protein (GFAP) immunohistochemistry
332(1)
6.5 Hemeoxygenase (HO) HO-1 and HO-2 immunochemistry
332(1)
6.6 Semiquantitative analysis of images
332(1)
6.7 Transmission electron microscopy
333(1)
6.8 Biochemical analysis
333(1)
6.9 Hemeoxygenase HO-1 and HO-2 ELISA
333(1)
6.10 Brain water content
333(1)
6.11 Statistical analysis of the data
334(1)
7 Results obtained
334(12)
7.1 Cardiac arrest and blood-brain barrier permeability
334(1)
7.2 Cardiac arrest and brain edema formation
334(2)
7.3 Cardiac arrest and HO-1 and HO-2 biochemistry
336(3)
7.4 Brain pathology
339(1)
7.5 Neuronal changes
339(1)
7.6 Astrocytic changes
339(1)
7.7 HO-1 and HO-2 immunoreactivity
339(3)
7.8 Myelin changes
342(1)
7.9 Methylene blue treatment induces neuroprotection
342(4)
8 Discussion
346(31)
Acknowledgments
349(1)
Conflict of Interest
350(1)
References
350(27)
Chapter 8 Multimodal imaging in the differential diagnosis of glioma recurrence from treatment-related effects: A protocol for systematic review and network meta-analysis
377(8)
Huijing Chen
Yanwen Luo
Cong Li
Wengang Zhan
Qijia Tan
Caijun Xie
Aruna Sharma
Hari Shanker Sharma
Zhiqiang Zhang
1 Introduction
378(1)
2 Methods
379(2)
2.1 Literature search
379(1)
2.2 Selection of studies and data collection process
379(1)
2.3 Quality evaluation
380(1)
2.4 Geometry of the network
381(1)
2.5 Statistical analysis
381(1)
3 Protocol and registration
381(1)
4 Discussion
381(4)
Funding
382(1)
References
382(3)
Chapter 9 Manganese nanoparticles induce blood-brain barrier disruption, cerebral blood flow reduction, edema formation and brain pathology associated with cognitive and motor dysfunctions
385(22)
Aruna Sharma
Lianyuan Feng
Dafin F. Muresanu
Seaab Sahib
Z. Ryan Tian
Jose Vicente Lafuente
Anca D. Buzoianu
Rudy J. Castellani
Ala Nozari
Lars Wiklund
Hari Shanker Sharma
1 Introduction
386(1)
2 Materials and methods
387(2)
2.1 Animals
387(1)
2.2 Exposure to manganese nanoparticles
387(1)
2.3 Blood-brain barrier permeability
388(1)
2.4 Cerebral blood flow
388(1)
2.5 Brain edema formation and volume swelling
388(1)
2.6 Sensory motor functions
388(1)
2.7 Morphological analyses
389(1)
2.8 Statistical analyses of the data
389(1)
3 Results
389(9)
3.1 Effect of MnO2 nanoparticles on blood-brain barrier permeability
389(1)
3.2 Effect of MnO2 nanoparticles on cerebral blood flow
390(1)
3.3 Effect of MnO2 nanoparticles on brain edema formation and volume swelling
390(3)
3.4 Effect of MnO2 nanoparticles on neuronal injury
393(2)
3.5 Effect of MnO2 nanoparticles on sensory motor functions
395(3)
4 Discussion
398(9)
Acknowledgments
399(1)
Conflict of Interest
400(1)
References
400(7)
Chapter 10 Targeted therapy with anlotinib for a leptomeningeal spread recurrent glioblastoma patient
407
Cong Li
Wenyu Li
Shuang Dai
Aruna Sharma
Hari Shanker Sharma
Youliang Wu
1 Introduction
408(1)
2 Case presentation
408(2)
3 Discussion
410(2)
4 Conclusion
412
References
413
Dr. Hari Shanker Sharma, Professor of Neurobiology (MRC), Docent in Neuroanatomy (UU) is currently working in Uppsala University Hospital, Department of Surgical Sciences, Division of Anesthesiology & Intensive Care Medicine, Uppsala University, Sweden. Dr Sharma obtained his Masters Degree from Bihar University with special expertise in Cell Biology in 1976 and was awarded the Gold Medal of Bihar University for securing 1st position in the 1st Class. Dr Sharma joined the group of Professor Prasanta Kumar Dey, a neurophysiologist, by training in the Department of Physiology, Institute of Medical; Sciences, Banaras Hindu University, Varanasi in 1977 to obtain his Doctor of Philosophy Degree (D.Phil.) in Neurosciences and was awarded his Ph.D. in 1982 on Blood-Brain Barrier in Stress.” After carrying out a series of Government of India funded Research Projects on the BBB and brain dysfunction (19821987), Dr Sharma joined the lab of Neuropathology at Uppsala University with Professor Yngve Olsson in 1988 to investigate passage of tracer transport across the BBB caused by stress or traumatic insults to the Brain and Spinal cord at light and electron microscopy. Dr Sharma was awarded the prestigious Alexander von Humboldt Foundation Fellowship of German Government (19891991) to work on hyperthermia induced BBB dysfunction at the ultrastructural level in the laboratory of Professor Jorge Cervós-Navarro (a living Legend in Neuropathology in Europe”). Dr Sharma again joined Uppsala University and established a network of collaboration on Experimental CNS Injury Research Group” as a lead investigator with eminent collaborators in various parts of Europe, USA, and Australia (1991). On his work on hyperthermia Dr Sharma received the prestigious Neuroanatomy award Rönnows Research prize” of Uppsala University for best neuroanatomical research of the year 1996” followed by the Award of the Degree of Doctor of Medical Sciences of Uppsala University in Neuroanatomy in 1999 and selected for the Best Thesis Award of the Medical faculty, The Hwassers Prize” of 1999. On his meticulous works on the Blood Brain barrier and Brain edema (20002003) Dr. Sharma earned the prestigious title of Docent in Neuroanatomy” of Medical Faculty, Uppsala University in April 2004. Currently his main research interest is Neuroprotection and Neuroregeneration, in relation to the Blood-brain barrier in stress, trauma, and drugs of abuse in health and disease. Dr. Sharma on his research on brain pathology and neuroprotection in different models received the prestigious award from The Laerdal Foundation of Acute Medicine, Stavanger, Norway, in 2005 followed by Distinguished International Scientists Collaboration Award by National Institute on Drug Abuse (NIDA), Baltimore, MD (20062008). His recent work on 5-HT3 receptor mediated neuroprotection in morphine withdrawal induced neurotoxicity won the coveted prize of Best Investigator Award 2008 and Best Scientific Presentation by European Federation of the International Association for Study of Pain (ISAP), and Awarded during their VI Annual Meeting in Lisbon, September 912, 2008. His recent research is aimed to find out the role of nanoparticles in Neurodegeneration and Neuroprotection using various treatment strategies that is supported by European Aerospace Research and Development (EOARD), London, UK and US Air Force Research Laboratory, Wright Patterson Air Force Base, Dayton, Oh, USA. On his works on Bloodbrain barrier in hypertension and diabetes together with Romanian colleagues, University of Medicine and Pharmacy Iuliu Hatieganu,” Cluj-Napoca, Romania awarded Dr. Sharma with Honorary Doctorate of Medical Sciences in 2009. Dr Sharmas work over 30 years on the blood-brain barrier and brain edema won him the US Neurosurgeon Dr Anthony Marmarou Award (2011) by the International Brain Edema Society at their 15th Congress in Tokyo, Japan, November 2011. His works on Nanoneuroscience and development of nanomedicine to treat the CNS injuries has won accolades at various Government and International Scotties or Organization across the World. Accordingly Dr Sharma was decorated with the most prestigious ”Hind Rattan Award 2012” on the eve of Republic Day of India in January 2012 and Mahatma Gandhi Pravasi Gold Medal in October 2012 in House of Lords, London, UK. Dr Sharma was also invited to organize and chair Nanosymposium in Society for Neuroscience meetings in Chicago (2009), San Diego (2010), Washington DC (2011) and New Orleans (2012). Dr Sharma has published over 380 research papers, 75 reviews, 12 monographs, and 70 international book chapters and edited 15 book volumes. Aruna Sharma, MD is currently Secretary of Research at Uppsala University Hospital, Uppsala University, Sweden. She obtained her Bachelor of Science in 1971 and trained in Indian Medicine up to 1977 and engaged in medical research from 1978 to 1986 in India on hyperthermia induced brain dysfunction in the lab of Hari Sharma and Prasanta Kumar Dey under University Grants Commission and Indian Council of Medical Research

Her main interest is now focused on Indian Medicinal drugs and their effects on the Central Nervous System Function, toxicology, neurorepair and neuroprotection. She is also investigating neurotoxicological profiles of many Ayurvedic traditional drugs with special reference to those containing metal oxide or metal ashes.